Using the safety and feasibility data from these first-in-human trials demonstrating that intermittent D+Q was well tolerated in 50 subjects (NCT 02874989 and NCT 02848131), combined with the efficacy data in mouse models, we initiated a Phase I study of senolytic therapy in older adults with early-stage symptomatic AD, SToMP-AD (Senolytic Therapy to Modulate the Progression of Alzheimers Disease, NCT04063124) (107)
Responses of 11 out of 23 subjects were recorded
Aqua/Water/Eau, Peg-8, Cellulose, Butylene Glycol, Glycerin, Peg-7 Glyceryl Cocoate, Hamamelis Virginiana (Witch Hazel) Water, Phenoxyethanol, Carbomer, Saccharide Isomerate, Benzophenone-3, Panthenol, Alcohol, Chlorphenesin, Sodium Hydroxide, Fragrance, Disodium EDTA, Ananas Sativus (Pineapple) Fruit Extract, Propylene Glycol, Citric Acid, Guar Hydroxypropyltrimonium Chloride, Sodium Citrate, Panthenyl Triacetate, Taraxacum Officinale (Dandelion) Rhizome/Root Extract, Pantolactone, Hydroxyethylcellulose, Hydroxypropylcellulose, Centaurea Cyanus Flower Extract, BHT, Ethylhexylglycerin, Titanium Dioxide (CI 77891), Fd&C Blue No
Therefore, there is growing interest in determining which other epigenetic modifications might play a key regulatory role
